跳至主要内容
临床试验/NCT01632059
NCT01632059已完成不适用

Examination of ADMA (Asymmetric-dimethylarginine)-Serum Level and DDAH II (Dimethylarginine Dimethylaminohydrolase)- Polymorphism in Patients With Severe Sepsis and Septic Shock as Prognostic Value

Universitätsklinikum Hamburg-Eppendorf1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2012年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
120
试验地点
1
主要终点
ADMA serum levels

研究概览

简要总结

Examination of ADMA (Asymmetric-Dimethylarginine)-serum level and DDAH II (Dimethylarginine Dimethylaminohydrolase)- Polymorphism in patients with severe Sepsis and septic shock as prognostic value.

This study looks into ADMA as a good prognostic factor for sepsis. Further more the dependency of the ADMA level to the DDAH II polymorphisms is reviewed this study.

详细描述

Secondary targets are the mortality (28 days ICU), the length of hospitalisation in ICU and peripheral station, the severity of the illness (SAPS II score), the SOFA-score values in the progress and the procalcitonin values in the progress

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • septical shock

排除标准

  • primary cardiogenic shock
  • pregnancy
  • breastfeeding
  • non compliance
  • moribund status

结局指标

主要结局

ADMA serum levels

时间窗: 7 days

measuring of ADMA serum levels on day 1, 3, 7

次要结局

  • severity of illness(28 days)
  • DDAH Ii polymorphism(28 days)
  • hospitalisation (ICU and peripheral)(28 days)
  • 28 day mortality(28 day)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验